Skip to main content
Top
Published in: Trials 1/2008

Open Access 01-12-2008 | Research

Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials

Authors: Irene Floriani, Nicole Rotmensz, Elena Albertazzi, Valter Torri, Marisa De Rosa, Carlo Tomino, Fillipo de Braud

Published in: Trials | Issue 1/2008

Login to get access

Abstract

Background

Although interim analysis approaches in clinical trials are widely known, information on current practice of planned monitoring is still scarce. Reports of studies rarely include details on the strategies for both data monitoring and interim analysis. The aim of this project is to investigate the forms of monitoring used in cancer clinical trials and in particular to gather information on the role of interim analyses in the data monitoring process of a clinical trial. This study focused on the prevalence of different types of interim analyses and data monitoring in cancer clinical trials.

Methods

Source of investigation were the protocols of cancer clinical trials included in the Italian registry of clinical trials from 2000 to 2005. Evaluation was restricted to protocols of randomised studies with a time to event endpoint, such as overall survival (OS) or progression free survival (PFS). A template data extraction form was developed and tested in a pilot phase. Selection of relevant protocols and data extraction were performed independently by two evaluators, with differences in the data assessment resolved by consensus with a third reviewer, referring back to the original protocol. Information was obtained on a) general characteristics of the protocol b) disease localization and patient setting; c) study design d) interim analyses; e) DSMC.

Results

The analysis of the collected protocols reveals that 70.7% of the protocols incorporate statistical interim analysis plans, but only 56% have also a DSMC and be considered adequately planned. The most concerning cases are related to lack of any form of monitoring (20.0% of the protocols), and the planning of interim analysis, without DSMC (14.7%).

Conclusion

The results indicate that there is still insufficient attention paid to the implementation of interim analysis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Armitage P: Interim analysis in clinical trials. Statistics in Medicine. 1991, 10: 925-37. 10.1002/sim.4780100613.CrossRefPubMed Armitage P: Interim analysis in clinical trials. Statistics in Medicine. 1991, 10: 925-37. 10.1002/sim.4780100613.CrossRefPubMed
2.
go back to reference Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MKB, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA, the DAMOCLES study group: Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005, 9 (7): 1-238.CrossRef Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MKB, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA, the DAMOCLES study group: Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005, 9 (7): 1-238.CrossRef
3.
go back to reference Hughes M, Pocock J: Stopping rules and estimation problems in clinical trials. Statistics in Medicine. 1988, 7: 1231-42. 10.1002/sim.4780071204.CrossRefPubMed Hughes M, Pocock J: Stopping rules and estimation problems in clinical trials. Statistics in Medicine. 1988, 7: 1231-42. 10.1002/sim.4780071204.CrossRefPubMed
4.
go back to reference Armitage P, McPherson CK, Rowe BC: Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A. 1969, 132: 235-244. 10.2307/2343787.CrossRef Armitage P, McPherson CK, Rowe BC: Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A. 1969, 132: 235-244. 10.2307/2343787.CrossRef
5.
go back to reference Korn E, Freidlin B, George S: Data monitoring and large apparent treatment effects. Controlled Clinical Trials. 2004, 1: 67-69. 10.1016/S0197-2456(03)00109-0.CrossRef Korn E, Freidlin B, George S: Data monitoring and large apparent treatment effects. Controlled Clinical Trials. 2004, 1: 67-69. 10.1016/S0197-2456(03)00109-0.CrossRef
6.
go back to reference Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH: Randomised trials stopped early for benefit: a systematic review. JAMA. 2005, 294: 2203-9. 10.1001/jama.294.17.2203.CrossRefPubMed Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, Lacchetti C, Leung TW, Darling E, Bryant DM, Bucher HC, Schunemann HJ, Meade MO, Cook DJ, Erwin PJ, Sood A, Sood R, Lo B, Thompson CA, Zhou Q, Mills E, Guyatt GH: Randomised trials stopped early for benefit: a systematic review. JAMA. 2005, 294: 2203-9. 10.1001/jama.294.17.2203.CrossRefPubMed
7.
go back to reference Freedman LS, Spiegelhalter DJ, Parmar MKB: The what, why and how of Bayesian clinical trials monitoring. Statistics in Medicine. 1994, 13: 1371-1383. 10.1002/sim.4780131312.CrossRefPubMed Freedman LS, Spiegelhalter DJ, Parmar MKB: The what, why and how of Bayesian clinical trials monitoring. Statistics in Medicine. 1994, 13: 1371-1383. 10.1002/sim.4780131312.CrossRefPubMed
8.
go back to reference Whitehead J: The design and analysis of sequential clinical trials. 1992, Chichester, Ellis Horwood, 2 Whitehead J: The design and analysis of sequential clinical trials. 1992, Chichester, Ellis Horwood, 2
9.
go back to reference Jennison C, Turnbull BW: Statistical approaches to interim monitoring of medical trials: a review and commentary. Statistical Science. 1990, 5: 299-317. 10.1214/ss/1177012099.CrossRef Jennison C, Turnbull BW: Statistical approaches to interim monitoring of medical trials: a review and commentary. Statistical Science. 1990, 5: 299-317. 10.1214/ss/1177012099.CrossRef
10.
go back to reference Piantadosi S: Clinical Trials: A Methodologic Perspective. 1997, New York, John Wiley & Sons Piantadosi S: Clinical Trials: A Methodologic Perspective. 1997, New York, John Wiley & Sons
11.
go back to reference Souhami RL: The clinical importance of early stopping of randomised trials in cancer treatments. Statistics in Medicine. 1994, 13: 1293-5. 10.1002/sim.4780131303.CrossRefPubMed Souhami RL: The clinical importance of early stopping of randomised trials in cancer treatments. Statistics in Medicine. 1994, 13: 1293-5. 10.1002/sim.4780131303.CrossRefPubMed
12.
go back to reference Filibeck U, Addis A, Tomino C, Martini N: European Clinical Trials Directive: the Italian position. Lancet. 2004, 363: 1651-2. 10.1016/S0140-6736(04)16222-3.CrossRefPubMed Filibeck U, Addis A, Tomino C, Martini N: European Clinical Trials Directive: the Italian position. Lancet. 2004, 363: 1651-2. 10.1016/S0140-6736(04)16222-3.CrossRefPubMed
13.
go back to reference Pocock SJ, Hughes MJ: Practical problems in interim analyses with particular regard to estimation. Controlled Clinical Trials. 1989, 10: 209S-221S. 10.1016/0197-2456(89)90059-7.CrossRefPubMed Pocock SJ, Hughes MJ: Practical problems in interim analyses with particular regard to estimation. Controlled Clinical Trials. 1989, 10: 209S-221S. 10.1016/0197-2456(89)90059-7.CrossRefPubMed
Metadata
Title
Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials
Authors
Irene Floriani
Nicole Rotmensz
Elena Albertazzi
Valter Torri
Marisa De Rosa
Carlo Tomino
Fillipo de Braud
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Trials / Issue 1/2008
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-9-46

Other articles of this Issue 1/2008

Trials 1/2008 Go to the issue